HC Wainwright Has Optimistic Outlook of ASND FY2026 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at HC Wainwright boosted their FY2026 earnings estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Thursday, September 10th. HC Wainwright analyst M. Kapoor now forecasts that the biotechnology company will post earnings of $3.93 per share for the year, up from their previous estimate of $3.85. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is $3.69 per share. HC Wainwright also issued estimates for Ascendis Pharma A/S’s Q2 2027 earnings at $2.35 EPS, Q3 2027 earnings at $3.05 EPS, Q4 2027 earnings at $4.25 EPS and FY2027 earnings at $11.30 EPS.

Several other analysts also recently commented on the company. Royal Bank Of Canada increased their target price on Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Oppenheimer upped their price target on Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an “outperform” rating in a report on Tuesday, September 1st. Bank of America dropped their price objective on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Wall Street Zen upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Finally, Stifel Nicolaus lowered their price objective on shares of Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $310.00.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $264.92 on Monday. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15. The firm has a market cap of $16.53 billion, a P/E ratio of 20.55 and a beta of 0.35. The company has a 50 day moving average of $257.36 and a 200 day moving average of $242.38. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in the business. Perceptive Advisors LLC increased its holdings in Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after buying an additional 450,000 shares during the last quarter. Sei Investments Co. raised its position in Ascendis Pharma A/S by 24.8% in the first quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock worth $80,318,000 after acquiring an additional 69,673 shares during the period. Fred Alger Management LLC boosted its stake in shares of Ascendis Pharma A/S by 106.3% during the 4th quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock worth $75,084,000 after acquiring an additional 181,408 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its stake in shares of Ascendis Pharma A/S by 68.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 225,155 shares of the biotechnology company’s stock worth $60,053,000 after acquiring an additional 91,822 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its position in shares of Ascendis Pharma A/S by 243.0% during the 1st quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock valued at $56,907,000 after acquiring an additional 178,415 shares during the period.

Insider Transactions at Ascendis Pharma A/S

In other news, Director Jean-Jacques Bienaimé purchased 2,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the purchase, the director directly owned 2,900 shares in the company, valued at $714,357. This trade represents a 222.22% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by corporate insiders.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.